Search

Your search keyword '"Rathkopf, Dana E."' showing total 149 results
Start Over Author "Rathkopf, Dana E." Publication Year Range Last 3 years
149 results on '"Rathkopf, Dana E."'

1. Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer

Author

Truong, Hong, Breen, Kelsey, Nandakumar, Subhiksha, Sjoberg, Daniel D., Kemel, Yelena, Mehta, Nikita, Lenis, Andrew T., Reisz, Peter A., Carruthers, Jessica, Benfante, Nicole, Joseph, Vijai, Khurram, Aliya, Gopalan, Anuradha, Fine, Samson W., Reuter, Victor E., Vickers, Andrew J., Birsoy, Ozge, Liu, Ying, Walsh, Michael, Latham, Alicia, Mandelker, Diana, Stadler, Zsofia K., Pietzak, Eugene, Ehdaie, Behfar, Touijer, Karim A., Laudone, Vincent P., Slovin, Susan F., Autio, Karen A., Danila, Daniel C., Rathkopf, Dana E., Eastham, James A., Chen, Yu, Morris, Michael J., Offit, Kenneth, Solit, David B., Scher, Howard I., Abida, Wassim, Robson, Mark E., and Carlo, Maria I.

Published
2023
Full Text
View/download PDF

2. LIBERTAS: A degendered and transgender-inclusive phase 3 study of apalutamide (APA) plus intermittent vs continuous androgen deprivation therapy (ADT) in participants (pts) with metastatic hormone-sensitive prostate cancer (mHSPC).

Author

Azad, Arun, primary, Musto, Clark, additional, Netanel, Shir, additional, Zhang, Tian, additional, Rathkopf, Dana E., additional, Badillo, Marco Antonio, additional, Dong, Qiang, additional, Morgans, Alicia K., additional, Runcie, Karie, additional, Dos Santos, Alex, additional, Bhaumik, Amitabha, additional, Mundle, Suneel, additional, McCarthy, Sharon, additional, Lopez- Gitlitz, Angela Mennicke, additional, Batavia, Ashita S., additional, Sanchez, Daniel P., additional, Wildgust, Mark A., additional, and Agarwal, Neeraj, additional

Published
2024
Full Text
View/download PDF

3. Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

Author

Autio, Karen A., Antonarakis, Emmanuel S., Mayer, Tina M., Shevrin, Daniel H., Stein, Mark N., Vaishampayan, Ulka N., Morris, Michael J., Slovin, Susan F., Heath, Elisabeth I., Tagawa, Scott T., Rathkopf, Dana E., Milowsky, Matthew I., Harrison, Michael R., Beer, Tomasz M., Balar, Arjun V., Armstrong, Andrew J., George, Daniel J., Paller, Channing J., Apollo, Arlyn, Danila, Daniel C., Graff, Julie N., Nordquist, Luke, Dayan Cohn, Erica S., Tse, Kin, Schreiber, Nicole A., Heller, Glenn, and Scher, Howard I.

Published
2021
Full Text
View/download PDF

4. FIGURE 1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

5. Data from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

6. Data from Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer

Author

Chen, Naiyu, primary, McGrath, Colleen B., primary, Ericsson, Caroline I., primary, Vaselkiv, Jane B., primary, Rencsok, Emily M., primary, Stopsack, Konrad H., primary, Guard, Hannah E., primary, Autio, Karen A., primary, Rathkopf, Dana E., primary, Enting, Deborah, primary, Bitting, Rhonda L., primary, Mateo, Joaquin, primary, Githiaka, Charles W., primary, Chi, Kim N., primary, Cheng, Heather H., primary, Davis, Ian D., primary, Anderson, Simon G., primary, Badal, Simone Ann Marie, primary, Bjartell, Anders, primary, Russnes, Kjell M., primary, Heath, Elisabeth I., primary, Pomerantz, Mark M., primary, Henegan, John C., primary, Hyslop, Terry, primary, Esteban, Emilio, primary, Omlin, Aurelius, primary, McDermott, Ray, primary, Fay, Andre P., primary, Popoola, Ademola Alabi, primary, Ragin, Camille, primary, Nowak, Joel, primary, Gerke, Travis, primary, Kantoff, Philip W., primary, George, Daniel J., primary, Penney, Kathryn L., primary, and Mucci, Lorelei A., primary

Published
2024
Full Text
View/download PDF

7. Supplementary Table 1. from Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer

Author

Chen, Naiyu, primary, McGrath, Colleen B., primary, Ericsson, Caroline I., primary, Vaselkiv, Jane B., primary, Rencsok, Emily M., primary, Stopsack, Konrad H., primary, Guard, Hannah E., primary, Autio, Karen A., primary, Rathkopf, Dana E., primary, Enting, Deborah, primary, Bitting, Rhonda L., primary, Mateo, Joaquin, primary, Githiaka, Charles W., primary, Chi, Kim N., primary, Cheng, Heather H., primary, Davis, Ian D., primary, Anderson, Simon G., primary, Badal, Simone Ann Marie, primary, Bjartell, Anders, primary, Russnes, Kjell M., primary, Heath, Elisabeth I., primary, Pomerantz, Mark M., primary, Henegan, John C., primary, Hyslop, Terry, primary, Esteban, Emilio, primary, Omlin, Aurelius, primary, McDermott, Ray, primary, Fay, Andre P., primary, Popoola, Ademola Alabi, primary, Ragin, Camille, primary, Nowak, Joel, primary, Gerke, Travis, primary, Kantoff, Philip W., primary, George, Daniel J., primary, Penney, Kathryn L., primary, and Mucci, Lorelei A., primary

Published
2024
Full Text
View/download PDF

8. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study

Author

Saad, Fred, Efstathiou, Eleni, Attard, Gerhardt, Flaig, Thomas W, Franke, Fabio, Goodman, Oscar B, Jr, Oudard, Stéphane, Steuber, Thomas, Suzuki, Hiroyoshi, Wu, Daphne, Yeruva, Kesav, De Porre, Peter, Brookman-May, Sabine, Li, Susan, Li, Jinhui, Thomas, Shibu, Bevans, Katherine B, Mundle, Suneel D, McCarthy, Sharon A, and Rathkopf, Dana E

Published
2021
Full Text
View/download PDF

9. FIGURE 2 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

10. Supplementary Table S4 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

11. Supplementary Figure S2 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

12. TABLE 1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

13. TABLE 3 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

14. TABLE 4 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

15. TABLE 2 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

16. Marital status, living arrangement, and survival among individuals with advanced prostate cancer in the International Registry for Men with Advanced Prostate Cancer

Author

Chen, Naiyu, primary, McGrath, Colleen B., additional, Ericsson, Caroline I., additional, Vaselkiv, Jane B., additional, Rencsok, Emily M., additional, Stopsack, Konrad H., additional, Guard, Hannah E., additional, Autio, Karen A., additional, Rathkopf, Dana E., additional, Enting, Deborah, additional, Bitting, Rhonda L., additional, Mateo, Joaquin, additional, Githiaka, Charles Waihenya., additional, Chi, Kim N., additional, Cheng, Heather H., additional, Davis, Ian D., additional, Anderson, Simon G., additional, Badal, Simone Ann Marie., additional, Bjartell, Anders, additional, Russnes, Kjell M., additional, Heath, Elisabeth I., additional, Pomerantz, Mark M., additional, Henegan, John C., additional, Hyslop, Terry, additional, Esteban, Emilio, additional, Omlin, Aurelius, additional, McDermott, Ray, additional, Fay, Andre P., additional, Popoola, Ademola Alabi., additional, Ragin, Camille, additional, Nowak, Joel, additional, Gerke, Travis, additional, Kantoff, Philip W., additional, George, Daniel J., additional, Penney, Kathryn L., additional, and Mucci, Lorelei A., additional

Published
2024
Full Text
View/download PDF

17. Supplementary Methods S1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

18. A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer

Author

Zhao, Shuang G., Sperger, Jamie M., Schehr, Jennifer L., McKay, Rana R., Emamekhoo, Hamid, Singh, Anupama, Schultz, Zachery D., Bade, Rory M., Stahlfeld, Charlotte N., Gilsdorf, Cole S., Hernandez, Camila I., Wolfe, Serena K., Mayberry, Richel D., Krause, Hannah M., Bootsma, Matt, Helzer, Kyle T., Rydzewski, Nicholas, Bakhtiar, Hamza, Shi, Yue, Blitzer, Grace, Kyriakopoulos, Christos E., Kosoff, David, Wei, Xiao X., Floberg, John, Sethakorn, Nan, Sharifi, Marina, Harari, Paul M., Huang, Wei, Beltran, Himisha, Choueiri, Toni K., Scher, Howard I., Rathkopf, Dana E., Halabi, Susan, Armstrong, Andrew J., Beebe, David J., Yu, Menggang, Sundling, Kaitlin E., Taplin, Mary-Ellen, and Lang, Joshua M.

Subjects
Prostate cancer -- Development and progression -- Prognosis, Tumor markers -- Genetic aspects -- Health aspects, Health care industry
Abstract

BACKGROUND. Neuroendocrine prostate cancer (NEPC) is an aggressive subtype, the presence of which changes the prognosis and management of metastatic prostate cancer. METHODS. We performed analytical validation of a Circulating Tumor Cell (CTC) multiplex RNA qPCR assay to identify the limit of quantification (LOQ) in cell lines, synthetic cDNA, and patient samples. We next profiled 116 longitudinal samples from a prospectively collected institutional cohort of 17 patients with metastatic prostate cancer (7 NEPC, 10 adenocarcinoma) as well as 265 samples from 139 patients enrolled in 3 adenocarcinoma phase II trials of androgen receptor signaling inhibitors (ARSIs). We assessed a NEPC liquid biomarker via the presence of neuroendocrine markers and the absence of androgen receptor (AR) target genes. RESULTS. Using the analytical validation LOQ, liquid biomarker NEPC detection in the longitudinal cohort had a per- sample sensitivity of 51.35% and a specificity of 91.14%. However, when we incorporated the serial information from multiple liquid biopsies per patient, a unique aspect of this study, the per-patient predictions were 100% accurate, with a receiver- operatingcurve (ROC) AUC of 1. In the adenocarcinoma ARSI trials, the presence of neuroendocrine markers, even while AR target gene expression was retained, was a strong negative prognostic factor. CONCLUSION. Our analytically validated CTC biomarker can detect NEPC with high diagnostic accuracy when leveraging serial samples that are only feasible using liquid biopsies. Patients with expression of NE genes while retaining AR- target gene expression may indicate the transition to neuroendocrine differentiation, with clinical characteristics consistent with this phenotype. FUNDING. NIH (DP2 OD030734, 1UH2CA260389, R01CA247479, and P30 CA014520), Department of Defense (PC190039 and PC200334), and Prostate Cancer Foundation (Movember Foundation--PCF Challenge Award)., Introduction The majority of prostate cancers are histologically classified as adenocarcinomas. Prostate adenocarcinoma is driven by androgens, expresses prostate-specific antigen (PSA) and other androgen receptor (AR) target genes, and responds [...]

Published
2022
Full Text
View/download PDF

19. Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer.

Author

Naiyu Chen, McGrath, Colleen B., Ericsson, Caroline I., Vaselkiv, Jane B., Rencsok, Emily M., Stopsack, Konrad H., Guard, Hannah E., Autio, Karen A., Rathkopf, Dana E., Enting, Deborah, Bitting, Rhonda L., Mateo, Joaquin, Githiaka, Charles W., Chi, Kim N., Cheng, Heather H., Davis, Ian D., Anderson, Simon G., Badal, Simone Ann Marie, Bjartell, Anders, and Russnes, Kjell M.

Abstract

Background: Studies have shown improved survival among individuals with cancer with higher levels of social support. Few studies have investigated social support and overall survival (OS) in individuals with advanced prostate cancer in an international cohort. We investigated the associations of marital status and living arrangements with OS among individuals with advanced prostate cancer in the International Registry for Men with Advanced Prostate Cancer (IRONMAN). Methods: IRONMAN is enrolling participants diagnosed with advanced prostate cancer (metastatic hormone-sensitive prostate cancer, mHSPC; castration-resistant prostate cancer, CRPC) from 16 countries. Participants in this analysis were recruited between July 2017 and January 2023. Adjusting for demographics and tumor characteristics, the associations were estimated using Cox regression and stratified by disease state (mHSPC, CRPC), age (<70, =70 years), and continent of enrollment (North America, Europe, Other). Results: We included 2,119 participants with advanced prostate cancer, of whom 427 died during up to 5 years of follow-up (median 6 months). Two-thirds had mHSPC. Most were married/in a civil partnership (79%) and 6% were widowed. Very few married participants were living alone (1%), while most unmarried participants were living alone (70%). Married participants had better OS than unmarried participants [adjusted HR: 1.44; 95% confidence interval (CI): 1.02-2.02]. Widowed participants had the worst survival compared with married individuals (adjusted HR: 1.89; 95% CI: 1.22-2.94). Conclusions: Among those with advanced prostate cancer, unmarried and widowed participants had worse OS compared with married participants. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Apalutamide (APA) plus intermittent versus continuous androgen-deprivation therapy (ADT) in participants (pts) with metastatic castration-sensitive prostate cancer (mCSPC): LIBERTAS phase 3 study design.

Author

Azad, Arun, Badillo, Marco Antonio, Dong, Qiang, Morgans, Alicia K., Rathkopf, Dana E., Runcie, Karie, Zhang, Tian, Pruthi, Raj, Bhaumik, Amitabha, Mundle, Suneel, McCarthy, Sharon, Lopez- Gitlitz, Angela Mennicke, Whalen, Jennifer, Batavia, Ashita S., Musto, Clark, Netanel, Shir, Sanchez, Daniel P., and Agarwal, Neeraj

Published
2024
Full Text
View/download PDF

21. Post radical prostatectomy (RP) PSA outcomes following 6 versus 18 months of perioperative androgen receptor signaling inhibitors (ARSI) in men with localized high-risk prostate cancer: Results of Part 2 of a randomized phase 2 trial.

Author

McKay, Rana R., Xie, Wanling, Yang, Xiaoyu, Acosta, Andres, Rathkopf, Dana E., Laudone, Vincent Paul, Bubley, Glenn, Einstein, David Johnson, Chang, Peter, Wagner, Andrew, Kane, Christopher J., Preston, Mark A., Kilbridge, Kerry L., Chang, Steven Lee, Choudhury, Atish Dipankar, Pomerantz, Mark, Trinh, Quoc-Dien, Kibel, Adam S., and Taplin, Mary-Ellen

Published
2024
Full Text
View/download PDF

22. Patient-reported health-related quality of life (HRQoL) in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH agonist with either bicalutamide or abiraterone acetate plus prednisone (AAP) and apalutamide (Apa) after radical...

Author

Hoffman, Karen E., Nguyen, Paul L., Rathkopf, Dana E., Zurita, Amado J., Spratt, Daniel Eidelberg, Dess, Robert Timothy, Liauw, Stanley L., Szmulewitz, Russell Zelig, Einstein, David Johnson, Bubley, Glenn, Yu, James B., An, Yi, Wong, Anthony C., Feng, Felix Y, McKay, Rana R., Rose, Brent S., Shin, Kee-Young, Kibel, Adam S., Taplin, Mary-Ellen, and Kollmeier, Marisa

Published
2024
Full Text
View/download PDF

23. First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Author

Rathkopf, Dana E., Patel, Manish R., Choudhury, Atish Dipankar, Rasco, Drew W., Lakhani, Nehal J., Hawley, Jessica E., Aparicio, Ana, Narayan, Vivek, Srinivas, Sandy, Runcie, Karie, Emamekhoo, Hamid, Reichert, Zachery R, Carducci, Michael Anthony, Wells, Amber L., Liu, Can, Kandimalla, Raju, Wu, Jiaju, Nguyen, Marie Huong, Pourdehnad, Michael, and Armstrong, Andrew J.

Published
2024
Full Text
View/download PDF

24. Patient-reported outcomes (PRO) in patients (pts) with BRCA1/2 -altered metastatic castration-resistant prostate cancer (mCRPC) receiving niraparib (NIRA) with abiraterone acetate and prednisone (AAP): Results from MAGNITUDE study.

Author

Rathkopf, Dana E., Roubaud, Guilhem, Chi, Kim N., Efstathiou, Eleni, Attard, Gerhardt, Olmos, David, Small, Eric J., Saad, Marniza, Castro, Elena, Kim, Won, Wu, Daphne, Bertzos, Kristi, Dibaj, Shiva, Zhang, Jenny, Francis, Peter St. John, and Smith, Matthew Raymond

Published
2024
Full Text
View/download PDF

25. External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer

Author

Halabi, Susan, primary, Yang, Qian, additional, Roy, Akash, additional, Luo, Bin, additional, Araujo, John C., additional, Logothetis, Christopher, additional, Sternberg, Cora N., additional, Armstrong, Andrew J., additional, Carducci, Michael A., additional, Chi, Kim N., additional, de Bono, Johann S., additional, Petrylak, Daniel P., additional, Fizazi, Karim, additional, Higano, Celestia S., additional, Morris, Michael J., additional, Rathkopf, Dana E., additional, Saad, Fred, additional, Ryan, Charles J., additional, Small, Eric J., additional, and Kelly, William Kevin, additional

Published
2023
Full Text
View/download PDF

26. Abstract 6489: Marital status, living arrangement, and overall survival among individuals with advanced prostate cancer in the IRONMAN cohort

Author

Chen, Naiyu, primary, McGrath, Colleen B., additional, Ericsson, Caroline I., additional, Vaselkiv, Jane B., additional, Sodipo, Michelle O., additional, Rencsok, Emily M., additional, Stopsack, Konrad H., additional, George, Daniel J., additional, Autio, Karen A., additional, Rathkopf, Dana E., additional, Penney, Kathryn L., additional, and Mucci, Lorelei A., additional

Published
2023
Full Text
View/download PDF

27. Supplementary Figure from A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors

Author

Choudhury, Atish D., primary, Higano, Celestia S., primary, de Bono, Johann S., primary, Cook, Natalie, primary, Rathkopf, Dana E., primary, Wisinski, Kari B., primary, Martin-Liberal, Juan, primary, Linch, Mark, primary, Heath, Elisabeth I., primary, Baird, Richard D., primary, García-Carbacho, Javier, primary, Quintela-Fandino, Miguel, primary, Barry, Simon T., primary, de Bruin, Elza C., primary, Colebrook, Steve, primary, Hawkins, George, primary, Klinowska, Teresa, primary, Maroj, Brijesh, primary, Moorthy, Ganesh, primary, Mortimer, Peter G., primary, Moschetta, Michele, primary, Nikolaou, Myria, primary, Sainsbury, Liz, primary, Shapiro, Geoffrey I., primary, Siu, Lillian L., primary, and Hansen, Aaron R., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Table 2 from Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate

Author

Attard, Gerhardt, primary, de Bono, Johann S., primary, Logothetis, Christopher J., primary, Fizazi, Karim, primary, Mukherjee, Som D., primary, Joshua, Anthony M., primary, Schrijvers, Dirk, primary, van den Eertwegh, Alfons J.M., primary, Li, Weimin, primary, Molina, Arturo, primary, Griffin, Thomas W., primary, Kheoh, Thian, primary, Ricci, Deborah S., primary, Zelinsky, Kathy, primary, Rathkopf, Dana E., primary, Scher, Howard I., primary, and Ryan, Charles J., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Data from A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors

Author

Choudhury, Atish D., primary, Higano, Celestia S., primary, de Bono, Johann S., primary, Cook, Natalie, primary, Rathkopf, Dana E., primary, Wisinski, Kari B., primary, Martin-Liberal, Juan, primary, Linch, Mark, primary, Heath, Elisabeth I., primary, Baird, Richard D., primary, García-Carbacho, Javier, primary, Quintela-Fandino, Miguel, primary, Barry, Simon T., primary, de Bruin, Elza C., primary, Colebrook, Steve, primary, Hawkins, George, primary, Klinowska, Teresa, primary, Maroj, Brijesh, primary, Moorthy, Ganesh, primary, Mortimer, Peter G., primary, Moschetta, Michele, primary, Nikolaou, Myria, primary, Sainsbury, Liz, primary, Shapiro, Geoffrey I., primary, Siu, Lillian L., primary, and Hansen, Aaron R., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Figure 1 from Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone

Author

Rathkopf, Dana E., primary, Antonarakis, Emmanuel S., primary, Shore, Neal D., primary, Tutrone, Ronald F., primary, Alumkal, Joshi J., primary, Ryan, Charles J., primary, Saleh, Mansoor, primary, Hauke, Ralph J., primary, Bandekar, Rajesh, primary, Maneval, Edna Chow, primary, de Boer, Carla J., primary, Yu, Margaret K., primary, and Scher, Howard I., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Table S2 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

Author

Autio, Karen A., primary, Klebanoff, Christopher A., primary, Schaer, David, primary, Kauh, John Sae Wook, primary, Slovin, Susan F., primary, Adamow, Matthew, primary, Blinder, Victoria S., primary, Brahmachary, Manisha, primary, Carlsen, Michelle, primary, Comen, Elizabeth, primary, Danila, Daniel C., primary, Doman, Thompson N., primary, Durack, Jeremy C., primary, Fox, Josef J., primary, Gluskin, Jill S., primary, Hoffman, David M., primary, Kang, Suhyun, primary, Kang, Praneet, primary, Landa, Jonathan, primary, McAndrew, Philomena F., primary, Modi, Shanu, primary, Morris, Michael J., primary, Novosiadly, Ruslan, primary, Rathkopf, Dana E., primary, Sanford, Rachel, primary, Chapman, Sonya C., primary, Tate, Courtney M., primary, Yu, Danni, primary, Wong, Phillip, primary, and McArthur, Heather L., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure 4 from Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate

Author

Attard, Gerhardt, primary, de Bono, Johann S., primary, Logothetis, Christopher J., primary, Fizazi, Karim, primary, Mukherjee, Som D., primary, Joshua, Anthony M., primary, Schrijvers, Dirk, primary, van den Eertwegh, Alfons J.M., primary, Li, Weimin, primary, Molina, Arturo, primary, Griffin, Thomas W., primary, Kheoh, Thian, primary, Ricci, Deborah S., primary, Zelinsky, Kathy, primary, Rathkopf, Dana E., primary, Scher, Howard I., primary, and Ryan, Charles J., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figure from Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors

Author

Stopsack, Konrad H., primary, Nandakumar, Subhiksha, primary, Arora, Kanika, primary, Nguyen, Bastien, primary, Vasselman, Samantha E., primary, Nweji, Barbara, primary, McBride, Sean M., primary, Morris, Michael J., primary, Rathkopf, Dana E., primary, Slovin, Susan F., primary, Danila, Daniel C., primary, Autio, Karen A., primary, Scher, Howard I., primary, Mucci, Lorelei A., primary, Solit, David B., primary, Gönen, Mithat, primary, Chen, Yu, primary, Berger, Michael F., primary, Schultz, Nikolaus, primary, Abida, Wassim, primary, and Kantoff, Philip W., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figure S2 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

Author

Autio, Karen A., primary, Klebanoff, Christopher A., primary, Schaer, David, primary, Kauh, John Sae Wook, primary, Slovin, Susan F., primary, Adamow, Matthew, primary, Blinder, Victoria S., primary, Brahmachary, Manisha, primary, Carlsen, Michelle, primary, Comen, Elizabeth, primary, Danila, Daniel C., primary, Doman, Thompson N., primary, Durack, Jeremy C., primary, Fox, Josef J., primary, Gluskin, Jill S., primary, Hoffman, David M., primary, Kang, Suhyun, primary, Kang, Praneet, primary, Landa, Jonathan, primary, McAndrew, Philomena F., primary, Modi, Shanu, primary, Morris, Michael J., primary, Novosiadly, Ruslan, primary, Rathkopf, Dana E., primary, Sanford, Rachel, primary, Chapman, Sonya C., primary, Tate, Courtney M., primary, Yu, Danni, primary, Wong, Phillip, primary, and McArthur, Heather L., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Materials and Methods from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

Author

Autio, Karen A., primary, Klebanoff, Christopher A., primary, Schaer, David, primary, Kauh, John Sae Wook, primary, Slovin, Susan F., primary, Adamow, Matthew, primary, Blinder, Victoria S., primary, Brahmachary, Manisha, primary, Carlsen, Michelle, primary, Comen, Elizabeth, primary, Danila, Daniel C., primary, Doman, Thompson N., primary, Durack, Jeremy C., primary, Fox, Josef J., primary, Gluskin, Jill S., primary, Hoffman, David M., primary, Kang, Suhyun, primary, Kang, Praneet, primary, Landa, Jonathan, primary, McAndrew, Philomena F., primary, Modi, Shanu, primary, Morris, Michael J., primary, Novosiadly, Ruslan, primary, Rathkopf, Dana E., primary, Sanford, Rachel, primary, Chapman, Sonya C., primary, Tate, Courtney M., primary, Yu, Danni, primary, Wong, Phillip, primary, and McArthur, Heather L., primary

Published
2023
Full Text
View/download PDF

37. Data from Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors

Author

Stopsack, Konrad H., primary, Nandakumar, Subhiksha, primary, Arora, Kanika, primary, Nguyen, Bastien, primary, Vasselman, Samantha E., primary, Nweji, Barbara, primary, McBride, Sean M., primary, Morris, Michael J., primary, Rathkopf, Dana E., primary, Slovin, Susan F., primary, Danila, Daniel C., primary, Autio, Karen A., primary, Scher, Howard I., primary, Mucci, Lorelei A., primary, Solit, David B., primary, Gönen, Mithat, primary, Chen, Yu, primary, Berger, Michael F., primary, Schultz, Nikolaus, primary, Abida, Wassim, primary, and Kantoff, Philip W., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Table 3 from Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate

Author

Attard, Gerhardt, primary, de Bono, Johann S., primary, Logothetis, Christopher J., primary, Fizazi, Karim, primary, Mukherjee, Som D., primary, Joshua, Anthony M., primary, Schrijvers, Dirk, primary, van den Eertwegh, Alfons J.M., primary, Li, Weimin, primary, Molina, Arturo, primary, Griffin, Thomas W., primary, Kheoh, Thian, primary, Ricci, Deborah S., primary, Zelinsky, Kathy, primary, Rathkopf, Dana E., primary, Scher, Howard I., primary, and Ryan, Charles J., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Table 1 from Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate

Author

Attard, Gerhardt, primary, de Bono, Johann S., primary, Logothetis, Christopher J., primary, Fizazi, Karim, primary, Mukherjee, Som D., primary, Joshua, Anthony M., primary, Schrijvers, Dirk, primary, van den Eertwegh, Alfons J.M., primary, Li, Weimin, primary, Molina, Arturo, primary, Griffin, Thomas W., primary, Kheoh, Thian, primary, Ricci, Deborah S., primary, Zelinsky, Kathy, primary, Rathkopf, Dana E., primary, Scher, Howard I., primary, and Ryan, Charles J., primary

Published
2023
Full Text
View/download PDF

40. First look at the baseline characteristics of participants in IRONMAN, the international registry for men with advanced prostate cancer.

Author

Mucci, Lorelei A, primary, Vinson, Jake, additional, Gerke, Travis A., additional, Hyslop, Terry, additional, Howard, Lauren, additional, Dreicer, Robert, additional, Rathkopf, Dana E., additional, Chi, Kim N., additional, Esteban, Emilio, additional, Enting, Deborah, additional, Bjartell, Anders, additional, Tagawa, Scott T., additional, Nanus, David M., additional, Ong, Michael, additional, Barata, Pedro C., additional, Hotte, Sebastien J., additional, Grant, Marie, additional, Villanti, Paul, additional, Kantoff, Philip W., additional, and George, Daniel J., additional

Published
2023
Full Text
View/download PDF

41. FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP).

Author

Nguyen, Paul L., primary, Kollmeier, Marisa, additional, Rathkopf, Dana E., additional, Hoffman, Karen E., additional, Zurita, Amado J., additional, Spratt, Daniel Eidelberg, additional, Dess, Robert Timothy, additional, Liauw, Stanley L., additional, Szmulewitz, Russell Zelig, additional, Einstein, David Johnson, additional, Bubley, Glenn, additional, Yu, James B., additional, An, Yi, additional, Wong, Anthony C., additional, Feng, Felix Y, additional, McKay, Rana R., additional, Rose, Brent S., additional, Shin, Kee-Young, additional, Kibel, Adam S., additional, and Taplin, Mary-Ellen, additional

Published
2023
Full Text
View/download PDF

42. Niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Second interim analysis (IA2) of MAGNITUDE.

Author

Efstathiou, Eleni, primary, Smith, Matthew Raymond, additional, Sandhu, Shahneen, additional, Attard, Gerhardt, additional, Saad, Marniza, additional, Olmos, David, additional, Castro, Elena, additional, Roubaud, Guilhem, additional, Gomes, Andrea Juliana, additional, Small, Eric Jay, additional, Rathkopf, Dana E., additional, Gurney, Howard, additional, Jung, Wonho, additional, Mason, Gary, additional, Francis, Peter St. John, additional, Wang, George C., additional, Wu, Daphne, additional, Diorio, Brooke, additional, Lopez- Gitlitz, Angela Mennicke, additional, and Chi, Kim N., additional

Published
2023
Full Text
View/download PDF

43. A phase 2 study of immunogenic cell death inducer PT-112 in patients with metastatic castration-resistant prostate cancer.

Author

Bryce, Alan Haruo, primary, Karp, Daniel D., additional, Tagawa, Scott T., additional, Nordquist, Luke T., additional, Rathkopf, Dana E., additional, Adra, Nabil, additional, Dorff, Tanya B., additional, Baeck, Johan, additional, O'Donnell, Joseph Francis, additional, Ames, Tyler David, additional, Yim, Christina Y., additional, Price, Matthew, additional, and Scher, Howard I., additional

Published
2023
Full Text
View/download PDF

44. Impact of run-in treatment with abiraterone acetate and prednisone (AAP) in the MAGNITUDE study of niraparib (NIRA) and AAP in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.

Author

Castro, Elena, primary, Chi, Kim N., additional, Sandhu, Shahneen, additional, Olmos, David, additional, Attard, Gerhardt, additional, Saad, Marniza, additional, Gomes, Andrea Juliana, additional, Rathkopf, Dana E., additional, Smith, Matthew Raymond, additional, Kang, Taek Won, additional, Cruz, Felipe Melo, additional, Basso, Umberto, additional, Mason, Gary, additional, del Corral, Adam, additional, Dibaj, Shiva, additional, Wu, Daphne, additional, Diorio, Brooke, additional, Lopez- Gitlitz, Angela Mennicke, additional, Tural, Deniz, additional, and Small, Eric Jay, additional

Published
2023
Full Text
View/download PDF

45. A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors

Author

Choudhury, Atish D, Higano, Celestia S, De Bono, Johann S, Cook, Natalie, Rathkopf, Dana E, Wisinski, Kari B, Martin-Liberal, Juan, Linch, Mark, Heath, Elisabeth I, Baird, Richard D, García-Carbacho, Javier, Quintela-Fandino, Miguel, Barry, Simon T, De Bruin, Elza C, Colebrook, Steve, Hawkins, George, Klinowska, Teresa, Maroj, Brijesh, Moorthy, Ganesh, Mortimer, Peter G, Moschetta, Michele, Nikolaou, Myria, Sainsbury, Liz, Shapiro, Geoffrey I, Siu, Lillian L, Hansen, Aaron R, Institut Català de la Salut, [Choudhury AD] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. [Higano CS] Department of Medical Oncology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington. [de Bono JS] Drug Development Unit, The Institute of Cancer Research and Royal Marsden, London, United Kingdom. [Cook N] The Christie NHS Foundation Trust and The University of Manchester, Manchester, United Kingdom. [Rathkopf DE] Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, New York. [Wisinski KB] Carbone Cancer Center, University of Wisconsin–Madison, Madison, Wisconsin. [Martin-Liberal J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Choudhury, Atish D [0000-0001-9344-6631], de Bono, Johann S [0000-0002-2034-595X], Cook, Natalie [0000-0003-2606-1082], Wisinski, Kari B [0000-0003-3535-0652], Heath, Elisabeth I [0000-0003-1381-2713], Baird, Richard D [0000-0001-7071-6483], García-Carbacho, Javier [0000-0002-6109-8449], Quintela-Fandino, Miguel [0000-0003-1648-1964], Barry, Simon T [0000-0002-8511-0588], Moorthy, Ganesh [0000-0003-1637-8465], Mortimer, Peter G [0000-0003-2900-2336], Shapiro, Geoffrey I [0000-0002-3331-4095], Siu, Lillian L [0000-0002-3500-0540], Hansen, Aaron R [0000-0002-2363-8707], and Apollo - University of Cambridge Repository

Subjects
Male, Cancer Research, Aniline Compounds, Lung Neoplasms, Càncer - Tractament, Abiraterone Acetate, Prostatic Neoplasms, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Prostate-Specific Antigen, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Neoplasms [DISEASES], neoplasias [ENFERMEDADES], Oncology, Chromones, Carcinoma, Non-Small-Cell Lung, Neoplasms, Fosfodiesterases - Inhibidors, Humans, Prednisone, acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de fosfodiesterasas [COMPUESTOS QUÍMICOS Y DROGAS], Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Phosphodiesterase Inhibitors [CHEMICALS AND DRUGS]
Abstract

Advanced Solid Tumors; PI3K beta/delta inhibitor Tumores sólidos avanzados; Inhibidor de PI3K beta/delta Tumors sòlids avançats; Inhibidor de PI3K beta/delta Purpose: To characterize safety and tolerability of the selective PI3Kβ inhibitor AZD8186, identify a recommended phase II dose (RP2D), and assess preliminary efficacy in combination with abiraterone acetate or vistusertib. Patients and Methods: This phase I open-label study included patients with advanced solid tumors, particularly prostate cancer, triple-negative breast cancer, and squamous non–small cell lung cancer. The study comprised four arms: (i) AZD8186 monotherapy dose finding; (ii) monotherapy dose expansion; (iii) AZD8186/abiraterone acetate (with prednisone); and (iv) AZD8186/vistusertib. The primary endpoints were safety, tolerability, and identification of the RP2D of AZD8186 monotherapy and in combination. Secondary endpoints included pharmacokinetics (PK), pharmacodynamics, and tumor and prostate-specific antigen (PSA) responses. Results: In total, 161 patients were enrolled. AZD8186 was well tolerated across all study arms, the most common adverse events being gastrointestinal symptoms. In the monotherapy dose-finding arm, four patients experienced dose-limiting toxicities (mainly rash). AZD8186 doses of 60-mg twice daily [BID; 5 days on, 2 days off (5:2)] and 120-mg BID (continuous and 5:2 dosing) were taken into subsequent arms. The PKs of AZD8186 were dose proportional, without interactions with abiraterone acetate or vistusertib, and target inhibition was observed in plasma and tumor tissue. Monotherapy and combination therapy showed preliminary evidence of limited antitumor activity by imaging and, in prostate cancer, PSA reduction. Conclusions: AZD8186 monotherapy had an acceptable safety and tolerability profile, and combination with abiraterone acetate/prednisone or vistusertib was also tolerated. There was preliminary evidence of antitumor activity, meriting further exploration of AZD8186 in subsequent studies in PI3Kβ pathway–dependent cancers. This study was sponsored by AstraZeneca. We thank the patients and their doctors and caregivers who participated in this study. We acknowledge support in Cambridge from Cancer Research UK, Experimental Cancer Medicine Center, NIHR Biomedical Research Center, and NIHR Cambridge Clinical Research Center. Research at the Christie NHS Foundation Trust was supported by the NIHR Manchester Clinical Research Facility and Manchester Experimental Cancer Medicine Center award. We also thank Martine Roudier (AstraZeneca) for providing analysis data of tumor tissue biopsies, and Wolfram Brugger and Caroline Kennedy (AstraZeneca, Cambridge, UK). Abiraterone acetate was kindly provided by Janssen. Medical writing and editorial assistance were provided by Bioscript Medical, Macclesfield, UK, and funded by AstraZeneca.

Published
2022

46. Health-related quality of life (HRQoL) and pain in the MAGNITUDE study of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.

Author

Rathkopf, Dana E., primary, Roubaud, Guilhem, additional, Chi, Kim N., additional, Sandhu, Shahneen, additional, Efstathiou, Eleni, additional, Attard, Gerhardt, additional, Olmos, David, additional, Lee, Ji Youl, additional, Small, Eric Jay, additional, Gomes, Andrea Juliana, additional, Saad, Marniza, additional, Castro, Elena, additional, Tural, Deniz, additional, Mason, Gary, additional, Bevans, Katherine B., additional, Trudeau, Jeremiah, additional, Francis, Peter St. John, additional, Wang, George C., additional, Lopez-Gitlitz, Angela, additional, and Smith, Matthew Raymond, additional

Published
2022
Full Text
View/download PDF

47. Gene-by-gene analysis in the MAGNITUDE study of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.

Author

Sandhu, Shahneen, primary, Attard, Gerhardt, additional, Olmos, David, additional, Efstathiou, Eleni, additional, Castro, Elena, additional, Rathkopf, Dana E., additional, Smith, Matthew Raymond, additional, Roubaud, Guilhem, additional, Small, Eric Jay, additional, Gomes, Andrea Juliana, additional, Saad, Marniza, additional, Tural, Deniz, additional, Thomas, Shibu, additional, Urtishak, Karen, additional, Gormley, Michael, additional, Mason, Gary, additional, Diorio, Brooke, additional, Wang, George C., additional, Lopez-Gitlitz, Angela, additional, and Chi, Kim N., additional

Published
2022
Full Text
View/download PDF

48. Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality

Author

Keegan, Niamh M., primary, Vasselman, Samantha E., additional, Barnett, Ethan S., additional, Nweji, Barbara, additional, Carbone, Emily A., additional, Blum, Alexander, additional, Morris, Michael J., additional, Rathkopf, Dana E., additional, Slovin, Susan F., additional, Danila, Daniel C., additional, Autio, Karen A., additional, Scher, Howard I., additional, Kantoff, Philip W., additional, Abida, Wassim, additional, and Stopsack, Konrad H., additional

Published
2022
Full Text
View/download PDF

49. Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide

Author

Pan, Alexander, primary, Reingold, Rachel E., additional, Zhao, Jimmy L., additional, Moy, Andrea, additional, Kraehenbuehl, Lukas, additional, Dranitsaris, George, additional, McBride, Sean M., additional, Scher, Howard I., additional, Kollmeier, Marisa A., additional, Xiao, Han, additional, Rathkopf, Dana E., additional, and Lacouture, Mario E., additional

Published
2022
Full Text
View/download PDF

50. A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors

Author

Choudhury, Atish D., primary, Higano, Celestia S., additional, de Bono, Johann S., additional, Cook, Natalie, additional, Rathkopf, Dana E., additional, Wisinski, Kari B., additional, Martin-Liberal, Juan, additional, Linch, Mark, additional, Heath, Elisabeth I., additional, Baird, Richard D., additional, García-Carbacho, Javier, additional, Quintela-Fandino, Miguel, additional, Barry, Simon T., additional, de Bruin, Elza C., additional, Colebrook, Steve, additional, Hawkins, George, additional, Klinowska, Teresa, additional, Maroj, Brijesh, additional, Moorthy, Ganesh, additional, Mortimer, Peter G., additional, Moschetta, Michele, additional, Nikolaou, Myria, additional, Sainsbury, Liz, additional, Shapiro, Geoffrey I., additional, Siu, Lillian L., additional, and Hansen, Aaron R., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results